China Life Insurance
VC Fund
Bukit Merah, Singapore
China Life Insurance is a VC fund in Bukit Merah focused on Health Care and Artificial Intelligence. China Life Insurance (Group) Company and its subsidiaries (hereinafter referred to as China Life) constitute the largest commercial insurance group in Mainland China. It is the only state-owned insurance group with an asset exceeding 1 trillion RMB yuan. It is also one of the largest institutional investors in China's capital market.In2011 its insurance premium income hit 357.8 billion RMB yuan. Life premium income accounted for 34.75% of the Mainland's life market share. By the end of 2011, its total asset reached 1.9562 trillion RMB yuan. (Figures provided have not been audited.)China Life Insurance (Group) Company, headquartered in Beijing, is a large state-owned financial and insurance company. Its predecessor, PICC was founded in 1949 and the PICC (Life) Co., Ltd was set up in 1996 after its separation from the former PICC. In 1999, it was renamed China Life Insurance Company. With the approval of the State Council and the China Insurance Regulatory Commission, the former China Life Insurance Company was restructured as China Life Insurance (Group) Company in 2003. It has China Life Insurance Company Limited, China Life Asset Management Company Limited, China Life Property & Casualty Insurance Company Limited, China Life Pension Company Limited, China Life Insurance (Overseas) Company Limited, China Life Investment Holding Company Limited and Insurance Professional College as its subsidiaries. Its business covers life insurance, property & casualty insurance, pension plans (corporate annuity), asset management, industrial investment and overseas operations. Through capital operation, it has invested in several banks, security firms and other non-financial institutions.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries China Life Insurance invests in
Stages China Life Insurance invests in
Countries China Life Insurance invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
H.C. Tung
|
|||
Investment Focus
Industry
- Health Care 3 (23%)
- Artificial Intelligence 3 (23%)
- Biopharma 2 (15%)
- Electronics 2 (15%)
- Biotechnology 2 (15%)
Stage
- Series A 3 (23%)
- Series C 3 (23%)
- Post-IPO Equity 3 (23%)
- Private Equity 2 (15%)
- Series B 1 (8%)
Country
- China 11 (85%)
- United States 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chen Fanglei
Chief Supervisor
|
Chief Supervisor | Total investments: 0 | Find email | |
|
Cui Lanqin
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
H.C. Tung
Founder
|
Founder | Total investments: 0 | Find email | |
|
Liu Huimin
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Miao Jianmin
Vice Chairman, President, Director
|
Vice Chairman, President, Director | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $200M / Series A / Jun 01, 2026 | |
|
|
COFCO Fortune provides high-quality food to customers through a fully integrated value chain with many well-known retailers and other state-owned enterprises. | $3.1B / Private Equity / Jan 16, 2023 | |
|
|
Tongfu Microelectronics provides integrated circuit packaging and testing. They are the support of national policies and the pull of the market, driven by the demand of system manufacturers, the coordinated development of the industrial chain, the support of national industrial funds, and major special projects. | $369.6M / Post-IPO Equity / Nov 01, 2022 | |
|
|
China Electronics Corporation, through its subsidiaries, designs, develops, manufactures, sells, and services semiconductor and electronics components, computer and core computer parts, software and system integration, and telecommunication and consumer electronics. | $274M / Corporate Round / Oct 24, 2022 | |
|
|
Hanbon is a developer of chromatographic products for the biomedical industry. The company provides liquid chromatography products for laboratory analysis, small-scale tests, and pilot test scale-up. Hanbon offers various chromatography products such as analytical liquid chromatography and bio-lab laboratory chromatography systems. | $44.4M / Series C / Jun 13, 2022 | |
|
|
Saint Bella is a maternal and baby care center operator. | $15.8M / Series C / Mar 03, 2022 | |
|
|
China Mobile provides mobile telecommunications and related services in Mainland China and Hong Kong.Its portfolio of services comprises of local calls, domestic long distance calls, international long distance calls, intra-provincial roaming, inter-provincial roaming, and international roaming, caller identity display, caller restrictions, callwaiting, call forwarding, call holding, voice mail, conference calls, and others.In addition, the company offers data services, wireless data traffic services, telecommunications network planning design and consulting services, mobile data solutions, network planning and optimizing construction testing and supervising activities, technology support, designing and selling electronic communication products, and more.It was incorporated in 1997 and is based in Central, Hong Kong. China Mobile Limited is a subsidiary of China Mobile Hong Kong (BVI) Limited. | $3.8B / Post-IPO Equity / Dec 28, 2021 | |
|
|
METiS Pharmaceuticals is the world's first AI-driven drug formulation company. | $86M / Series A / Dec 13, 2021 | |
|
|
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation. | $86M / Series A / Dec 07, 2021 | |
|
|
Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions. | $188M / Series B / May 06, 2021 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does China Life Insurance invest in?
China Life Insurance invests primarily in Health Care, Artificial Intelligence and Biopharma startups, most often at Series A and Series C stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact China Life Insurance?
Public channels for China Life Insurance include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at China Life Insurance?
The team at China Life Insurance includes Chen Fanglei (Chief Supervisor), Cui Lanqin (Vice President) and H.C. Tung (Founder), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!